New clinical trial evidence shows that semaglutide, a medication commonly used for diabetes and obesity, slows biological aging in adults with HIV by 9 percent, according to epigenetic clock measurements.
Researchers have discovered that a medication regularly prescribed for diabetes and weight management may also help slow the body’s biological aging process. In a recent clinical trial, semaglutide, a GLP-1 receptor agonist, was found to reduce the pace of biological aging in adults living with HIV. This finding could reshape how we approach aging and health, especially for those at higher risk for age-related conditions.
What Scientists Noticed About GLP-1 Drugs and the Body
GLP-1 receptor agonists like semaglutide are best known for controlling blood sugar and supporting weight loss. Recently, researchers have started to investigate whether these medications might also affect how quickly our cells age.
Most prior evidence for this idea came from animal experiments or theoretical work. That changed with a new randomized, placebo-controlled clinical trial published in Nature Communications. The study included 108 adults with HIV-associated lipohypertrophy, a condition causing excess abdominal fat. About half of the group received weekly semaglutide injections, while the rest were given a placebo.
To track aging, researchers used “epigenetic clocks,” which measure chemical changes in DNA known as methylation. These changes help show how quickly cells are aging, regardless of a person’s actual age. Over 32 weeks, the team monitored these markers to see if semaglutide made a difference.
Inside the Data on How Aging Slowed Down
People living with HIV often experience faster biological aging, even when their infection is well managed. The study found that those who received semaglutide showed slower aging across several epigenetic clocks, each tracking aging in different organs and systems.
One major result came from the DunedinPACE clock, which predicts the rate of physical decline. It showed a 9 percent slower pace of aging in the semaglutide group. The PCGrimAge clock, associated with mortality risk, also revealed slower aging in those taking the drug.
These benefits appeared across multiple systems, including the brain, heart, kidneys, liver, and metabolic health. This suggests that semaglutide could offer more than just support for weight or blood sugar,it may influence broader aspects of health.
What Might Be Happening Inside the Body
Researchers think semaglutide may slow aging by reducing inflammation and easing metabolic stress. Chronic immune activation drives faster aging among people with HIV, and GLP-1 drugs seem to help lower this response.
By reducing visceral fat,the type that surrounds organs,semaglutide may decrease harmful signals that speed up aging throughout the body.
Why This News Could Matter for More Than One Group
Although this research focused on people with HIV, the findings may be important for a wider group.
Many of the biological processes we study in HIV are also central to aging in the general population. Because these processes can emerge earlier or be more pronounced in people with HIV, this community can help us identify interventions that may improve healthspan more broadly.
Emerging data also suggest that GLP-1 drugs may reprogram certain cells in different organs, which could help explain why we see effects across multiple aging clocks.
Backing this up, a pilot study published in npj Aging found that after 24 weeks of semaglutide, 42 percent of HIV patients with fatty liver disease had a slower rate of aging, and almost half had longer telomeres, which are DNA markers linked to better physical function.
Looking Ahead as the Research Continues
Researchers emphasize that semaglutide is not a cure for aging or a way to make people younger.
We are not saying that semaglutide reverses aging or makes people younger.
Larger studies are needed to confirm these results and determine the best dosing and treatment duration. Experts are also interested in whether combining GLP-1 drugs with lifestyle changes like diet and exercise could enhance the benefits.
The Stein Institute for Research on Aging is developing “aging dashboards” that use epigenetic clocks. These could help doctors personalize treatments to address aging-related changes before major health problems develop.
For now, these findings suggest that medications already used for other health conditions might also help slow biological aging, potentially benefiting a broader range of people in the future.
Source: News Medical